Assessment of HyperQ Signal for Detecting Ischemia During Dobutamine Stress ECG
Recruitment status was Recruiting
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||An Assessment of the HyperQ Signal for Detecting Ischemia During Dobutamine Stress Echocardiography (DSE)|
- HyperQ Signal recorded during the DES Test
- DES Outcome/ Angiography
|Study Start Date:||March 2006|
|Estimated Study Completion Date:||February 2007|
Subjects referred for Dobutamine Stress Echocardiography who will sign an Informed consent form will go through the test. High resolution ECG from 12 leads will be recorded using BSP's HyperQ system before, during and following the Echo testing. This wil be done without interfering or affecting any aspect of the normal procedure. Standard Protocol will be used with standard test termination indications.
The Diagnostic stage will include analysis of the hyperQ signal, aiming to classify results as ischemic or non-ischemic.
The HyperQ data will be compared to DSE results which will be used as the "gold standard" for this study unless Angiography results are obtained.
An additional comparison evaluation will be performed to assess the advantage of the HyperQ results on the ST-changes results obtained from conventional ECG.In addition all recruited subjects will be followed for up to 12 months.During this period a phone call will be performed every 3 months to evaluate cardiac status, hospitalization and especially Angiography procedures.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00310622
|Contact: David Rosenman, MD||+972-50-8685923|
|Contact: Nechi Almogy, MDfirstname.lastname@example.org|
|Cardiology Department, Shaarey Zedek Hospital||Recruiting|
|Principal Investigator:||David Rosenmann, MD||Shaarey Zedek Hospital, Jerusalem, Israel|